XSXi Shen

Xi Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xi Shen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Hanwen Huang

    Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China

    1 shared publication
  • Huiping Yao

    Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, 197 Ruijin Er Road, 200025, Shanghai, China

    1 shared publication
  • Jin Wei

    Department of Psychology University of Virginia 22903 Charlottesville VA United States

    1 shared publication
  • Jing Wang

    Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China

    1 shared publication
  • Luan Tao

    Department of Ophthalmology Ruijin Hospital Affiliated Medical School Shanghai Jiao tong University 200025 Shanghai China

    1 shared publication
  • Na Li

    Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    Ocular blood flow alterations in autoimmune diseases: insights from optical coherence tomography angiography

    by Luan Tao, Jin Wei, Xi Shen

    The global incidence of autoimmune diseases is on the rise, leading to a corresponding increase in ocular complications associated with these conditions. Autoimmune pathologies can directly target ocular tissues via inflammatory mediators or induce endothelial dysfunction and microvascular alterations that compromise ocular integrity. These mechanisms give rise to a broad spectrum of ocular manifestations. In this review, optical coherence tomography angiography (OCTA)-detected changes in the eye are examined in the context of systemic autoimmune and inflammatory diseases. These imaging biomarkers show promise as novel indicators for identifying relapse risk and subclinical inflammatory stages in systemic autoimmune disorders.


  • Open Access

    Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage

    by Shuang Gao, Zhongjing Lin, Yisheng Zhong, Xi Shen

    Neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR) is a devastating ocular disease with poor prognosis. Intravitreal ranibizumab injection (IVR) has been used as adjuvant therapy of surgical interventions preoperatively or intraoperatively. This study aimed to determine the efficacy and safety of combined IVR as adjuvant therapy in treating NVG with vitreous hemorrhage (VH) in PDR. A total of 39 NVG patients with VH (39 eyes) received IVR 3 to 5 days before surgery, and then they were assigned to either pars plana vitrectomy (PPV) + Ahmed glaucoma valve (AGV) implantation (Group 1, n = 22) or PPV + AGV implantation + intraoperative IVR (Group 2, n = 17). Patients were followed up for at least 9 months. Intraocular pressure (IOP), anti-glaucoma medications, best corrected visual acuity (BCVA), surgical success rates and postoperative complications were compared. Results showed that IOP decreased promptly after surgery and was notably maintained at a mid-term follow-up in both groups, and no significant differences were observed (all p > 0.05). Additional intraoperative IVR significantly reduced postoperative recurrent VH and iris neovascularization (p = 0.047, p = 0.025, respectively). There was no remarkable difference in postoperative anti-glaucoma medications, BCVA and complications between two groups (all p > 0.05). In conclusion, preoperative and intraoperative IVR as adjuvant therapy of AGV implantation combined with PPV could be a safe and effective treatment for NVG with VH in PDR. An additional intraoperative anti-VEGF injection could significantly reduce postoperative VH and iris neovascularization.


  • Open Access

    Inhibition of Ferroptosis Ameliorates Photoreceptor Degeneration in Experimental Diabetic Mice

    by Sha Gao, Shuang Gao, Yanuo Wang, Na Li, Zijian Yang, Huiping Yao, Yanwei Chen, Yu Cheng, Yisheng Zhong, Xi Shen

    Diabetic retinopathy (DR) is a leading cause of vision impairment in the working-age population worldwide. Various modes of photoreceptor cell death contribute to the development of DR, including apoptosis and autophagy. However, whether ferroptosis is involved in the pathogenesis of photoreceptor degeneration in DR is still unclear. High-glucose (HG)-stimulated 661W cells and diabetic mice models were used for in vitro and in vivo experiments, respectively. The levels of intracellular iron, glutathione (GSH), reactive oxygen species (ROS), lipid peroxidation (MDA), and ferroptosis-related proteins (GPX4, SLC7A11, ACSL4, FTH1, and NCOA4) were quantified to indicate ferroptosis. The effect of ferroptosis inhibition was also assessed. Our data showed the levels of iron, ROS, and MDA were enhanced and GSH concentration was reduced in HG-induced 661W cells and diabetic retinas. The expression of GPX4 and SLC7A11 was downregulated, while the expression of ACSL4, FTH1, and NCOA4 was upregulated in the 661W cells cultured under HG conditions and in the photoreceptor cells in diabetic mice. Furthermore, the administration of the ferroptosis inhibitor ferrostatin-1 (Fer-1) obviously alleviated ferroptosis-related changes in HG-cultured 661W cells and in retinal photoreceptor cells in diabetic mice. Taken together, our findings suggest that ferroptosis is involved in photoreceptor degeneration in the development of the early stages of DR.